Some brighter views
21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."
Pages
59
Language
English
Published on
21/06/22
You may also be interested by these reports :
13/08/26
Ottobock continues to deliver, with a strong set of results in 1H26. Core revenues grew by +7.7% (organic +6.7%), largely supported by a strong EMEA ...
12/08/26
Demant reported better-than-expected Q2 results, with robust top-line growth across all segments. Profitability rose by double digits in H1, and ...
12/08/26
Over the past few years, hearing aid firms have disappointed the shareholders who have supported them, resulting in a heavy price being paid. ...
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...